Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation

Transplant Immunology

Volumn 25, Issue 2-3, 2011, Pages 153-158

  Nordlander, Anna ^a   Uhlin, Michael ^a   Ringdén, Olle ^a   Kumlien, Gunilla ^a   Hauzenberger, Dan ^a   Mattsson, Jonas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic stem cell transplantation; Rejection; Rituximab

Indexed keywords

ALEMTUZUMAB; ANTIBODY; CD34 ANTIBODY; CD34 ANTIGEN; CYCLOSPORIN A; HLA ANTIBODY; HLA ANTIGEN CLASS 1 ANTIBODY; HLA ANTIGEN CLASS 2 ANTIBODY; IMMUNOGLOBULIN; METHOTREXATE; PREDNISOLONE; RECEPTOR ANTIBODY; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CASE REPORT; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY TEST; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; FANCONI ANEMIA; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HLA MATCHING; HUMAN; IMMUNOMODULATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE;

ANTIBODIES; ANTIGENS, CD34; ANTILYMPHOCYTE SERUM; CHILD; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INFANT; MALE; MIDDLE AGED; PLASMA EXCHANGE; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80052329445     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2011.06.001     Document Type: Article

References (40)

1. Maris M., Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases. Immunologic Research 2003, 28:13-24.
2. Marmont A.M., Horowitz M.M., Gale R.P., Sobocinski K., Ash R.C., van Bekkum D.W., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
3. Mattsson J., Ringden O., Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2008, 14:165-170.
4. Cudkowicz G., Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. The Journal of Experimental Medicine 1971, 134:1513-1528.
5. Kiessling R., Hochman P.S., Haller O., Shearer G.M., Wigzell H., Cudkowicz G. Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. European Journal of Immunology 1977, 7:655-663.
6. Murphy W.J., Kumar V., Bennett M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. The Journal of Experimental Medicine 1987, 166:1499-1509.
7. Raff R.F., Deeg H.J., Loughran T.P., Graham T.C., Aprile J.A., Sale G.E., et al. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. Blood 1986, 68:861-868.
8. Raff R.F., Sandmaier B.M., Graham T., Loughran T.P., Pettinger M., Storb R. Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex. Experimental Hematology 1994, 22:893-897.
9. Barge A.J., Johnson G., Witherspoon R., Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989, 74:1477-1480.
10. Moeller E. Contact-induced cytotoxicity by lymphoid cells containing foreign isoantigens. Science 1965, 147:873-879.
11. Warren R.P., Storb R., Weiden P.L., Su P.J., Thomas E.D. Lymphocyte-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity in patients with aplastic anemia: distinguishing transfusion-induced sensitization from possible immune-mediated aplastic anemia. Transplantation Proceedings 1981, 13:245-247.
12. Nagata S., Okano S., Yonemitsu Y., Nakagawa K., Tomita Y., Yoshikai Y., et al. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice. Transplantation 2006, 82:689-698.
13. Taylor P.A., Ehrhardt M.J., Roforth M.M., Swedin J.M., Panoskaltsis-Mortari A., Serody J.S., et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007, 109:1307-1315.
14. Xu H., Chilton P.M., Tanner M.K., Huang Y., Schanie C.L., Dy-Liacco M., et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006, 108:3611-3619.
15. Sumitran-Karuppan S., Tyden G., Reinholt F., Berg U., Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transplant Immunology 1997, 5:321-327.
16. Tyden G., Kumlien G., Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003, 76:730-731.
17. Pelosi E., Valtieri M., Coppola S., Botta R., Gabbianelli M., Lulli V., et al. Identification of the hemangioblast in postnatal life. Blood 2002, 100:3203-3208.
18. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417:954-958.
19. Nordlander A., Mattsson J., Sundberg B., Sumitran-Holgersson S. Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation. Transplantation 2008, 86:686-696.
20. Tyden G., Donauer J., Wadstrom J., Kumlien G., Wilpert J., Nilsson T., et al. Implementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation 2007, 83:1153-1155.
21. Storb R., Deeg H.J., Fisher L., Appelbaum F., Buckner C.D., Bensinger W., et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988, 71:293-298.
22. Gluckman E., Rocha V., Ionescu I., Bierings M., Harris R.E., Wagner J., et al. Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. Biology of Blood and Marrow Transplantation 2007, 13:1073-1082.
23. Mattsson J., Uzunel M., Tammik L., Aschan J., Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001, 15:1976-1985.
24. Ball L.M., Bernardo M.E., Roelofs H., Lankester A., Cometa A., Egeler R.M., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110:2764-2767.
25. Sonnenday C.J., Warren D.S., Cooper M., Samaniego M., Haas M., King K.E., et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. American Journal of Transplantation 2004, 4:1315-1322.
26. Genberg H., Kumlien G., Wennberg L., Tyden G. Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab. Transplantation 2007, 84:S44-S47.
27. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
28. Mattsson J., Uzunel M., Brune M., Hentschke P., Barkholt L., Stierner U., et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. British Journal of Haematology 2001, 115:935-944.
29. Jaksch M., Mattsson J. The pathophysiology of acute graft-versus-host disease. Scandinavian Journal of Immunology 2005, 61:398-409.
30. Deneberg S., Lerner R., Ljungman P., Ringden O., Hagglund H. Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?. Medical Oncology 2007, 24:354-356.
31. Narimatsu H., Wake A., Miura Y., Tanaka H., Matsumura T., Takagi S., et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplantation 2005, 36:555-556.
32. Storb R., Prentice R.L., Thomas E.D., Appelbaum F.R., Deeg H.J., Doney K., et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. British Journal of Haematology 1983, 55:573-585.
33. Champlin R.E., Horowitz M.M., van Bekkum D.W., Camitta B.M., Elfenbein G.E., Gale R.P., et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989, 73:606-613.
34. Gluckman E., Broxmeyer H.A., Auerbach A.D., Friedman H.S., Douglas G.W., Devergie A., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. The New England Journal of Medicine 1989, 321:1174-1178.
35. Wagner J.E., Rosenthal J., Sweetman R., Shu X.O., Davies S.M., Ramsay N.K., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802.
36. Rocha V., Gluckman E. Clinical use of umbilical cord blood hematopoietic stem cells. Biology of Blood and Marrow Transplantation 2006, 12:34-41.
37. Takanashi M., Atsuta Y., Fujiwara K., Kodo H., Kai S., Sato H., et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010, 116:2839-2846.
38. Kaihara S., Okamoto M., Akioka K., Ogino S., Higuchi A., Kadotani Y., et al. Improved graft survival in ABO-incompatible living donor kidney transplantation. Transplantation Proceedings 2005, 37:1804-1805.
39. Gloor J.M., Lager D.J., Moore S.B., Pineda A.A., Fidler M.E., Larson T.S., et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003, 75:971-977.
40. Takanashi M., Fujiwara K., Tanaka H., Satake M., Nakajima K. The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion 2008, 48:791-793.